Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.725 USD | -0.11% | -8.64% | -9.16% |
Apr. 19 | Lyra Therapeutics, Inc. Announces Board Changes | CI |
Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
Financials (USD)
Sales 2024 * | 1.38M | Sales 2025 * | 782K | Capitalization | 283M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -82M | EV / Sales 2024 * | 205 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 362 x |
P/E ratio 2024 * |
-4.68
x | P/E ratio 2025 * |
-4.25
x | Employees | 88 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.47% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -0.11% | ||
1 week | -8.64% | ||
Current month | -23.47% | ||
1 month | -23.84% | ||
3 months | +3.93% | ||
6 months | +55.56% | ||
Current year | -9.16% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4.745 | +0.32% | 24 612 |
24-04-29 | 4.73 | +0.21% | 302,755 |
24-04-26 | 4.72 | -8.70% | 157,240 |
24-04-25 | 5.17 | -1.15% | 105,303 |
24-04-24 | 5.23 | +0.38% | 120,741 |
Delayed Quote Nasdaq, April 30, 2024 at 10:05 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.16% | 283M | |
+1.35% | 42.86B | |
+11.74% | 42.74B | |
+45.04% | 41.36B | |
-8.83% | 27.68B | |
+7.91% | 25.15B | |
-22.90% | 18.63B | |
+30.17% | 12.37B | |
-2.43% | 11.92B | |
+7.54% | 11.21B |
- Stock Market
- Equities
- LYRA Stock